恩度联合TP方案治疗晚期非小细胞肺癌的临床研究

Clinical study on treatment of advanced non-small cell lung cancer by endostar combined with TP regimen

目的观察重组人血管内皮抑制素(恩度)联合TP方案治疗非小细胞肺癌(NSCLC)的疗效和不良反应。方法 30例晚期NSCLC患者接受恩度联合TP化疗方案治疗≥2个周期,观察患者的总有效率(RR)、临床受益率(CBR)和不良反应。结果 30例中,2例获得完全缓解(6.7%),8例获得部分缓解(26.7%),16例疾病稳定(53.3%),有效率为33.3%,临床获益率为86.7%。3～4级毒性反应主要与化疗药物有关,包括白细胞减少、粒细胞减少、恶心呕吐、血小板下降、腹泻、乏力,发生率均不超过10%。结论恩度联合TP方案治疗晚期NSCLC效果良好,安全性好,值得进一步推广。

Objective To observe the curative effects of recombinant human endostatin(rh-endostar) combined with TP regimen on advanced non-small cell lung cancer(NSCLC) and the adverse reactions.Methods Thirty patients with advanced NSCLC received rh-endostar combined with TP regimen for 2 or more than 2 periods.Observation was made in the total effective rate,clinical benefit rate(CBR),and adverse reactions of those patients.Results Among the 30 cases,2 ones achieved complete remission(6.7%); 8 ones achieved partial remission(26.7%); 16 ones had stable diseases(53.3%).The effective rate was 33.3%,and the CBR was 86.7%.The toxic effects of grade 3-4 were mainly correlated to the chemotherapeutics,which included the decrease of leucocytes and granulocytes,nausea and vomit,the decline of platelets,diarrhea,and fatigue.Conclusion The treatment of advanced NSCLC by rh-endostar combined with TP regimen has good effects and safety.